Biotechnology has historically been anchored differently in clinical medicine, in the needs of patients, in hard-won norms around consent and human dignity. Whether that anchor holds firmly, as biotechnology is increasingly capitalized, scaled, and shaped by digital-sector values, is among the most consequential questions of our moment. Heritable modifications to the human genome, for instance, cannot be easily rolled back, and their consequences extend to people who cannot consent and communities that were never consulted. 

With the conviction that the voices most often absent from elite biotechnology convenings—including patients, disability communities, and the broader public—contain answers to essential questions on technological progress, join the University of Wisconsin – Madison in a sustained dialogue to reflect on what this convergence demands of us.

Guiding Questions

• How should human wellbeing, flourishing, integrity, and dignity guide decisions as we push the limits of genome editing?
• Why do scientists and investors decide how far this goes, and who else should have a say?
• Is the human germline a product to be sold, with a code to be debugged? 

---

---

Sponsors